These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

284 related items for PubMed ID: 24615631

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Female sexual function improved with ospemifene in postmenopausal women with vulvar and vaginal atrophy: results of a randomized, placebo-controlled trial.
    Constantine G, Graham S, Portman DJ, Rosen RC, Kingsberg SA.
    Climacteric; 2015 Apr; 18(2):226-32. PubMed ID: 25252699
    [Abstract] [Full Text] [Related]

  • 24. Ospemifene: A Novel Oral Therapy for Vulvovaginal Atrophy of Menopause.
    Reid RL, Black D, Derzko C, Portman D.
    J Obstet Gynaecol Can; 2020 Mar; 42(3):301-303. PubMed ID: 31932249
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Ospemifene for the treatment of vulvar and vaginal atrophy: A meta-analysis of randomized trials. Part II: Evaluation of tolerability and safety.
    Di Donato V, Schiavi MC, Iacobelli V, D'oria O, Kontopantelis E, Simoncini T, Muzii L, Benedetti Panici P.
    Maturitas; 2019 Mar; 121():93-100. PubMed ID: 30509754
    [Abstract] [Full Text] [Related]

  • 27. One-year long-term safety extension study of ospemifene for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterus.
    Simon JA, Lin VH, Radovich C, Bachmann GA, Ospemifene Study Group.
    Menopause; 2013 Apr; 20(4):418-27. PubMed ID: 23096251
    [Abstract] [Full Text] [Related]

  • 28. Profile of ospemifene in the breast.
    Berga SL.
    Reprod Sci; 2013 Oct; 20(10):1130-6. PubMed ID: 23945733
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Clinical effects of selective estrogen receptor modulators on vulvar and vaginal atrophy.
    Pinkerton JV, Stanczyk FZ.
    Menopause; 2014 Mar; 21(3):309-19. PubMed ID: 23777900
    [Abstract] [Full Text] [Related]

  • 32. Tissue selectivity of ospemifene: pharmacologic profile and clinical implications.
    Kangas L, Unkila M.
    Steroids; 2013 Dec 11; 78(12-13):1273-80. PubMed ID: 24055829
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Ospemifene: first global approval.
    Elkinson S, Yang LP.
    Drugs; 2013 May 11; 73(6):605-12. PubMed ID: 23605694
    [Abstract] [Full Text] [Related]

  • 37. Ospemifene, vulvovaginal atrophy, and breast cancer.
    Wurz GT, Soe LH, DeGregorio MW.
    Maturitas; 2013 Mar 11; 74(3):220-5. PubMed ID: 23332519
    [Abstract] [Full Text] [Related]

  • 38. Impact of vulvovaginal atrophy therapies on postmenopausal women's quality of life in the CRETA study measured by the Cervantes scale.
    Palacios S, Sánchez-Borrego R, Suárez Álvarez B, Lugo Salcedo F, González Calvo AJ, Quijano Martín JJ, Cancelo MJ, Fasero M.
    Maturitas; 2023 Jun 11; 172():46-51. PubMed ID: 37099983
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.